Insider · CIK 0001638474
Jeffrey W. Albers
Files at BPMC (Blueprint Medicines Corp), SYRE (Spyre Therapeutics, Inc.), KYMR (Kymera Therapeutics, Inc.). First filing Oct 28, 2024, latest Aug 10, 2026.
In brief
Jeffrey W. Albers files SEC Form 4 as director at BPMC (Blueprint Medicines Corp), and also at SYRE (Spyre Therapeutics, Inc.), KYMR (Kymera Therapeutics, Inc.). Since Oct 28, 2024, Jeffrey W. Albers has reported 0 open-market buys worth $0 and 13 open-market sells worth $9.4M, the latest filed on Aug 10, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey W. Albers has 0, so none is measured yet.
The newest scored trade: sold $2.4M of SYRE on Aug 7, 2026, filed Aug 10, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $3.1M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
SYRE: Spyre Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
KYMR: Kymera Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Spyre Therapeutics, Inc. | $2.4M 23,000 shares | -460% | +608% from low-0% from high | |
| 32Weak | Kymera Therapeutics, Inc. | $449k 5,000 shares | -100% | +348% from low0% from high | |
| 22Weak | Kymera Therapeutics, Inc. | $296k 5,000 shares | -100% | +185% from low0% from high | |
| 29Weak | Kymera Therapeutics, Inc. | $311k 6,349 shares | -100% | +107% from low-17% from high | |
| 13Weak | Blueprint Medicines Corp | $506k 5,000 shares | -3% | - | |
| 48Moderate | Blueprint Medicines Corp | $512k 5,766 shares | -4% | - | |
| 15Weak | Blueprint Medicines Corp | $659k 7,500 shares | -5% | - | |
| 20Weak | Blueprint Medicines Corp | $1.7M 15,161 shares | -9% | - | |
| 13Weak | Blueprint Medicines Corp | $511k 5,000 shares | -3% | - | |
| 20Weak | Blueprint Medicines Corp | $1.3M 15,000 shares | -9% | - | |
| 6Weak | Blueprint Medicines Corp | $510k 5,000 shares | -3% | - | |
| 13Weak | Spyre Therapeutics, Inc. | $246k 6,700 shares | -20% | - | |
| 0Weak | Spyre Therapeutics, Inc. | $11k 300 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 7, 2026 | SYRE SPYRE THERAPEUTICS INC | 18,000 0.02% of outstanding | $1.9M | Aug 7, 2026 | none |
| Aug 7, 2026 | SYRE SPYRE THERAPEUTICS INC | 5,000 0.01% of outstanding | $517k | Aug 7, 2026 | none |
| Dec 8, 2025 | KYMR KYMERA THERAPEUTICS INC | 5,000 0.01% of outstanding | $333k | Dec 8, 2025 | $296k |
| Oct 14, 2025 | KYMR KYMERA THERAPEUTICS, INC. | 5,000 0.01% of outstanding | $286k | Oct 13, 2025 | none |
| Jun 3, 2025 | KYMR KYMERA THERAPEUTICS, INC. | 6,349 0.01% of outstanding | $274k | Jun 3, 2025 | none |
| May 27, 2025 | BPMC Blueprint Medicines Corp | 5,000 0.01% of outstanding | $506k | May 27, 2025 | none |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | 5,161 0.01% of outstanding | $567k | Jan 21, 2025 | $2.4M |
| Jan 14, 2025 | BPMC Blueprint Medicines Corp | 5,000 0.08% of outstanding | $511k | Jan 13, 2025 | $1.9M |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | 15,000 0.25% of outstanding | $1.3M | Dec 19, 2024 | $510k |
| Nov 7, 2024 | BPMC Blueprint Medicines Corp | 5,000 0.01% of outstanding | $510k | Nov 7, 2024 | $1.7M |
| Oct 25, 2024 | SYRE SPYRE THERAPEUTICS INC | 7,000 0.01% of outstanding | $236k | Oct 25, 2024 | none |
Transactions
The newest 50 of 58 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $10.39 | $52k | 5,000 | Aug 10, 2026 |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $104.47 | $522k | 0 | Aug 10, 2026 |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Sessions LLC10b5-1 | -8,000 | $104.38 | $835k | 19,360 | Aug 10, 2026 |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Sessions LLC10b5-1 | -10,000 | $104.68 | $1.0M | 9,360 | Aug 10, 2026 |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 45,000 | Aug 10, 2026 |
| Jun 24, 2026 | KYMR Kymera Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,068 | $0.00 | $0 | 6,068 | Jun 25, 2026 |
| May 27, 2026 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,026 | $0.00 | $0 | 8,026 | May 29, 2026 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $14.18 | $71k | 5,000 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,748 | $89.32 | $245k | 2,252 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,252 | $90.30 | $203k | 0 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 7,000 | Dec 8, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $10.34 | $52k | 5,000 | Oct 14, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $59.19 | $296k | 0 | Oct 14, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 0 | Oct 14, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -5,777 | - | - | 144,755 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -144,755 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -92,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jun 25, 2025 | KYMR Kymera Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +3,902 | $128.12 | $500k | 150,532 | Jun 24, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,349 | $10.34 | $66k | 6,349 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,349 | $49.00 | $311k | 0 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,349 | $0.00 | $0 | 5,000 | Jun 3, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +5,000 | $36.05 | $180k | 151,630 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -4,350 | $101.02 | $439k | 147,280 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -650 | $101.93 | $66k | 146,630 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 92,500 | May 29, 2025 |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock | -5,766 | $88.80 | $512k | 146,630 | Mar 17, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +7,500 | $36.05 | $270k | 159,896 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,700 | $87.62 | $499k | 154,196 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,800 | $88.37 | $159k | 152,396 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 97,500 | Mar 14, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +10,000 | $36.05 | $361k | 167,557 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -7,561 | $109.11 | $825k | 159,996 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -7,400 | $109.92 | $813k | 152,596 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -200 | $110.61 | $22k | 152,396 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 105,000 | Jan 23, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +5,000 | $36.05 | $180k | 162,557 | Jan 15, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,000 | $102.28 | $511k | 157,557 | Jan 15, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 115,000 | Jan 15, 2025 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +15,000 | $36.05 | $541k | 172,557 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -3,920 | $88.28 | $346k | 168,637 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,180 | $89.01 | $461k | 163,457 | Dec 20, 2024 |
Questions about Jeffrey W. Albers
Answered from the filings on this page, as of the latest one.
Is Jeffrey W. Albers buying or selling?
In the last 12 months Jeffrey W. Albers reported 0 open-market buys worth $0 and 3 open-market sells worth $3.1M on SEC Form 4; the latest was sold $2.4M of SYRE on Aug 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey W. Albers's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey W. Albers has 0.
Where does Jeffrey W. Albers file Form 4?
Jeffrey W. Albers has filed Form 4 at BPMC (Blueprint Medicines Corp); SYRE (Spyre Therapeutics, Inc.); KYMR (Kymera Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.